Loading…
ELAN
Elanco Animal Health Inc
NYSE· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 28414H103
$22.69+0.62%Price as of Oct 23, 00:44 UTC · updated once a day, after the close
At a glance
Elanco Animal Health Inc (ELAN) is listed on NYSE and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in Indianapolis, United States and has 9,400 employees. The company is worth $11.33B. Revenue was $4.72B in fiscal 2025, up 6.2% from the year before. It reported a net loss of $232M. The share price is 18.9% below its 52-week high of $27.98. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Ken Griffin (Citadel Advisors), at $237.94M. In that quarter, 2 of them opened or added to the position and 1 reduced it. Over the last 30 days, company insiders sold $100.05K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $11.33B
- P/E
- —
- Forward P/E
- 17.6x
- P/B
- 1.7x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.41
- ROE
- -2.98%
- Profit margin
- -3.96%
- Revenue growth
- +10.20%
- Beta
- 1.71
- 52-week high
- $27.98
- 52-week low
- $19.40
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Ken GriffinAddedCitadel Advisors · Q2 2026$237.94M9.67M shares · 0.1% of portfolio- Israel EnglanderAddedMillennium Management · Q2 2026$67.08M2.73M shares · 0.0% of portfolio
- Cliff AsnessHeldAQR Capital Management · Q2 2026$5.45M224.31K shares · 0.0% of portfolio
- Lee AinslieReducedMaverick Capital · Q2 2026$2.41M98.1K shares · 0.0% of portfolio
Ray DalioHeldBridgewater Associates · Q2 2026$2.04M82.94K shares · 0.0% of portfolio- Two SigmaHeldTwo Sigma Investments · Q2 2026$310.63K12.62K shares · 0.0% of portfolio
Price over time
▼ -18.1% over 5Y.
today you would have $716.24▼ -28.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $22.63 | $12.11 | $14.90 | $12.22 | $28.38 | $30.67 | $29.45 | $31.53 | |
| P/E | 112.6x | — | 17.8x | — | — | — | — | 163.6x | 112.6x |
| P/S | 2.6x | 2.4x | 1.3x | 1.7x | 1.4x | 2.8x | 4.4x | 3.8x | 3.8x |
| P/B | 1.7x | 1.7x | 1.0x | 1.2x | 0.8x | 1.8x | 1.7x | 2.1x | 2.2x |
| EPS | -$0.47 | $0.68 | -$2.50 | -$0.16 | -$0.99 | -$1.30 | $0.18 | $0.28 | |
| Profit margin | -3.34% | -4.92% | 7.61% | -27.87% | -1.77% | -10.14% | -17.54% | 2.21% | 2.82% |
| ROE | -2.31% | -3.54% | 5.54% | -19.78% | -1.07% | -6.43% | -6.79% | 1.23% | 1.66% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$2.89
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Cash flow $2.89÷ 1 =$2.89
$2.89
1 methods answered, across 1 families.
$2.17
Room for errors in the reported numbers.
$22.69
-87.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RGENRepligen Corp | $178.71 | 244.8x | 4.8x | 0.00% | 1.99% | $11.35B |
| MOHMolina Healthcare Inc | $216.64 | — | 2.7x | 0.00% | -0.16% | $11.31B |
| TECHBIO-TECHNE Corp | $72.62 | 62.6x | 5.4x | 0.44% | 9.03% | $11.39B |
| TEMTempus AI, Inc. | $63.81 | — | 25.8x | 0.00% | -67.44% | $11.51B |
| UHSUniversal Health Services Inc | $188.13 | 7.7x | 1.5x | 0.43% | 20.95% | $11.09B |
| AVTRAvantor, Inc. | $17.15 | — | 2.1x | 0.00% | -9.70% | $11.6B |
About the company
- 9,400
- Indianapolis, United States